BUSULFANUM

Myelodysplastic Syndrome

Sawa Ito, MDSmall moleculePhase 4 / ApprovedActive

BB

70/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 72/ 100
Competitive Position: 65/ 100

Competitive context

295 Active assets in the Myelodysplastic Syndrome cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Sawa Ito, MD	Phase 4	BB
Nivestim City of Hope Medical Center	Phase 4	BB
Daunomycin OHSU Knight Cancer Institute	Phase 3	BB
CYTARABINE The First Affiliated Hospital of Soochow University	Phase 4	BB
Fludarabine City of Hope Medical Center	Phase 4	BB

View all 50 →

Same molecule, other indications

BUSULFANUM is also rated in:

myelodysplastic/myeloproliferative neoplasmActive

BBB

Indicative · Phase 2/3

76 / 100

graft versus host diseaseActive

BBB

Indicative · Phase 4

74 / 100

disease related to hematopoietic stem cell transplantActive

BBB

Indicative · Phase 3

74 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.